# Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

> **NCT05043649** · PHASE1 · TERMINATED · sponsor: **Monopar Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Advanced Soft-tissue Sarcoma

## Interventions

- **DRUG:** Camsirubicin

## Key facts

- **NCT ID:** NCT05043649
- **Lead sponsor:** Monopar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-22
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-05-13
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** lack of timely enrollment
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043649, "Camsirubicin + Pegfilgrastim to Determine MTD in ASTS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05043649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*